Muted Sanofi hits new 52-week low, shares face cautious analyst targets

Sanofi touches a fresh 52-week low on Euronext Paris as investors digest the appointment of a new global R&D head and recent Japan approval for subcutaneous Sarclisa, while analyst targets stay well above the current share price.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-22, 19:25.

Sanofi (FR0000120578) touched a new 52-week low on Euronext Paris on Monday, with the shares dipping to 71.50 euros according to market data from the Financial Times.Financial Times equity summary for Sanofi The move comes as the French pharma group adjusts its research leadership and highlights a fresh regulatory approval in Japan.

New research chief and Japan approval

Sanofi announced on June 22 that it has appointed Paulo Fontoura as Executive Vice President and Global Head of Research & Development Pharma, with a seat on the Executive Committee, effective September 1, 2026, according to an RTTNews summary of the company press release.RTTNews coverage of Sanofi leadership change The move follows a period of setbacks in some late-stage programs and is intended to sharpen the focus of the research portfolio.

In parallel, Japan's Ministry of Health, Labour and Welfare recently approved the subcutaneous formulation of Sanofi's multiple myeloma antibody Sarclisa in combination therapy, expanding treatment options in a major Asian oncology market, as reported by RTTNews and cited by several market services.RTTNews note on Sarclisa approval in Japan The product belongs to Sanofi's specialty care portfolio, where the company aims to build long-term growth.

Analyst consensus stays above spot price

Despite the fresh 52-week low, analyst consensus for Sanofi remains constructive, with MarketScreener compiling a predominant Buy stance and an average price target above 90 euros, well ahead of Monday's intraday levels around the low 70s.MarketScreener analyst consensus for Sanofi Deutsche Bank Research, for example, recently set a target of 95 euros while reiterating a Buy recommendation, according to German financial news reports summarizing the note.Marketscreener news overview citing Deutsche Bank

On Euronext Paris, Sanofi shares traded around 72.16 euros in recent dealings, down roughly 2.7 percent on the day, with intraday market data showing the new 52-week low at 71.50 euros and the 52-week high at 91.15 euros from October 2025.Euronext Paris quote overview for Sanofi The stock is a core member of the CAC 40 and Euro Stoxx 50, making its weakness visible in major European indices.

The product behind the stock

Among Sanofi's key growth drivers is the multiple myeloma therapy Sarclisa (isatuximab), now also available in a subcutaneous formulation in Japan following recent approval. The antibody targets CD38 on myeloma cells and is used in combination regimens for patients with relapsed or refractory disease.

Where the stock trades today

The Sanofi shares (FR0000120578) trade on 2026-06-22, 16:00, on Euronext Paris at 72.16 euros.

Sanofi at a glance

• Company: Sanofi S.A.
• ISIN: FR0000120578
• WKN: 920657
• Ticker: SAN
• Trading venue: Euronext Paris
• Price (as of 2026-06-22, 16:00): 72.16 EUR
• Market cap: about 91 billion EUR (as of 2026-06-22)
• Sector / industry: Pharmaceuticals & Biotechnology
• Index membership: CAC 40, Euro Stoxx 50, Stoxx Europe 600
• Next earnings date: not officially scheduled

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities.